Advertisement
APVO vs OTLK
Which Stock Would AI Choose? Aptevo Therapeutics (APVO) vs. Outlook Therapeutics (OTLK) Stock Comparison
Key Takeaways
- APVO (Aptevo Therapeutics) is a clinical-stage oncology biotech, while OTLK (Outlook Therapeutics) is a commercial-stage biopharma with a newly FDA-approved eye treatment, giving the two very different risk profiles.
- OTLK has a near-term, defined catalyst in its planned U.S. launch of LYTENAVA, whereas APVO remains tied to earlier-stage clinical data readouts.
- Both stocks are low-priced, highly volatile small-caps with histories of significant dilution and reverse stock splits, making relative performance unusually wide over the past year.
- APVO has delivered encouraging acute myeloid leukemia (AML) data for its lead candidate mipletamig, while OTLK has secured regulatory approval but faces execution and reimbursement risk in its U.S. rollout.
- Market sentiment toward OTLK has strengthened following the FDA decision, while sentiment on APVO has been driven by periodic, data-dependent spikes.
- For the latest headlines and intraday moves, explore APVO Major News and APVO Today's Price Move, as well as OTLK Major News and OTLK Today's Price Move.
- To see how AI evaluates these and other tickers in real time, explore Trending AI Robots.
Introduction
This stock comparison examines two small-cap biotechnology names that sit at very different stages of the drug-development lifecycle. Aptevo Therapeutics (APVO) is a clinical-stage oncology company whose value hinges on experimental cancer immunotherapy candidates, while Outlook Therapeutics (OTLK) has recently transitioned toward commercialization after securing U.S. regulatory approval for its lead product. For traders and investors weighing risk versus catalyst, the contrast between an early-stage pipeline story and an emerging commercial launch offers a useful lens on market positioning and relative performance in the biotech sector.
APVO Overview and Recent Performance
Aptevo Therapeutics (APVO) is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapy candidates for cancer using its ADAPTIR and ADAPTIR-FLEX platforms. Its lead candidate, mipletamig, is being evaluated in a Phase 1b/2 trial for frontline acute myeloid leukemia (AML, a cancer of the blood and bone marrow). In recent weeks, the company reported a high clinical benefit rate in a difficult-to-treat TP53-mutated AML population and announced that multiple treated patients had advanced to allogeneic stem cell transplant. Aptevo also highlighted progress in its next-generation trispecific programs and presented its multispecific platform at a major oncology meeting.
Despite these scientific milestones, APVO shares have experienced pronounced volatility, trading well below their 52-week highs. The company has relied on equity financing arrangements to extend its cash runway, which has contributed to dilution and weighed on sentiment. As a pre-revenue, clinical-stage business, its relative performance remains tightly linked to clinical data catalysts and financing events.
OTLK Overview and Recent Performance
Outlook Therapeutics (OTLK) is a biopharmaceutical company focused on LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD, a progressive eye disease causing vision loss). Following a prior Complete Response Letter from the U.S. Food and Drug Administration (FDA), the company successfully pursued a formal dispute resolution process and subsequently received FDA approval, becoming the first approved ophthalmic formulation of bevacizumab in the U.S. The company has guided to a U.S. launch before the end of the year and completed a roughly $55 million public offering to fund commercialization.
This regulatory milestone has driven a sharp re-rating in OTLK shares in recent months, though the stock remains below its yearly highs and faces execution, reimbursement, and pricing risks as it builds out a commercial organization. Unlike APVO, Outlook already records revenue from European launches, providing a modest commercial track record.
Trending AI Robots
Tickeron maintains a large library of AI trading bots that monitor and trade thousands of different tickers, but only a select subset earns a place in the curated Trending AI Robots section. These featured bots are chosen for their alignment with current market conditions, and they span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker coverage. Because each bot is built differently, traders can compare factors such as historical win rates, trade frequency, and risk profiles before selecting an approach that suits their objectives. Explore the Trending AI Robots page to review the currently available bots and find the strategies best matched to today's market environment.
Head-to-Head Comparison
The most important difference between these two companies is stage of development. OTLK has a marketed asset with a defined U.S. launch timeline and near-term revenue expectations, while APVO remains pre-revenue with value concentrated in earlier-stage clinical programs. This contrast shapes their respective risk profiles: Outlook's challenge is execution across commercialization, payer reimbursement, and competition from lower-cost compounded bevacizumab, whereas Aptevo's risk is scientific and regulatory, with success dependent on continued positive trial data.
On momentum, OTLK has benefited from a clear, binary-positive catalyst in the form of FDA approval, supporting a steadier upward trend in recent months. APVO, by contrast, has shown more episodic, data-driven moves. Both companies carry meaningful dilution risk and low share prices, but Outlook's revenue base and product approval provide a somewhat more defined path to value relative to Aptevo's earlier-stage pipeline. Sector exposure is similar—both are biotechnology—but their market positioning and catalyst timelines differ materially.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor OTLK in the current environment. The stock's regulatory approval, defined commercial launch, and recently improving trend consistency offer a more stable catalyst profile than the data-dependent, pre-revenue positioning of APVO. That said, this is a probabilistic assessment rather than a definitive prediction: both equities carry elevated volatility, and a stronger-than-expected clinical readout could shift relative momentum. Traders should weigh each company's distinct risk-reward profile against their own objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APVO is a Hold and OTLK is a StrongBuy.
APVO sees MACD Histogram crosses below signal line
APVO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 42 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (0.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OTLK in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 14, 2026
OTLK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 34 cases where OTLK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OTLK's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 66 cases where OTLK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for OTLK just turned positive on November 10, 2026. Looking at past instances where OTLK's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Following a +4.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where OTLK advanced for three days, in 201 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OTLK as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 50-day moving average for OTLK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OTLK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OTLK entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-10.223) is normal, around the industry mean (3.498). P/E Ratio (-0.623) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. OTLK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OTLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
APVO | OTLK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 95 | 63 | |
P/E GROWTH RATING 1..100 | 97 | 7 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OTLK's Valuation (11) in the Biotechnology industry is somewhat better than the same rating for APVO (52). This means that OTLK’s stock grew somewhat faster than APVO’s over the last 12 months.
OTLK's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APVO (100). This means that OTLK’s stock grew similarly to APVO’s over the last 12 months.
OTLK's SMR Rating (100) in the Biotechnology industry is in the same range as APVO (100). This means that OTLK’s stock grew similarly to APVO’s over the last 12 months.
OTLK's Price Growth Rating (63) in the Biotechnology industry is in the same range as APVO (95). This means that OTLK’s stock grew similarly to APVO’s over the last 12 months.
OTLK's P/E Growth Rating (7) in the Biotechnology industry is significantly better than the same rating for APVO (97). This means that OTLK’s stock grew significantly faster than APVO’s over the last 12 months.
| APVO | OTLK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Stochastic ODDS (%) | N/A | 1 day ago 79% |
| Momentum ODDS (%) | N/A | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Advances ODDS (%) | 8 days ago 76% | 1 day ago 83% |
| Declines ODDS (%) | 1 day ago 90% | 6 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APVO’s FA Score shows that 0 FA rating(s) are green while OTLK’s FA Score has 2 green FA rating(s).
- APVO’s FA Score: 0 green, 5 red.
- OTLK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APVO’s TA Score shows that 3 TA indicator(s) are bullish while OTLK’s TA Score has 5 bullish TA indicator(s).
- APVO’s TA Score: 3 bullish, 3 bearish.
- OTLK’s TA Score: 5 bullish, 4 bearish.
Price Growth
APVO (@Biotechnology) experienced а -44.53% price change this week, while OTLK (@Biotechnology) price change was +4.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
APVO is expected to report earnings on Nov 12, 2026.
OTLK is expected to report earnings on Dec 18, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OTLK and
Correlation & Price change
A.I.dvisor indicates that over the last year, OTLK has been loosely correlated with APVO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if OTLK jumps, then APVO could also see price increases.
| Ticker / NAME | Correlation To OTLK | 1D Price Change % | ||
|---|---|---|---|---|
| OTLK | 100% | +4.43% | ||
| APVO - OTLK | 45% Loosely correlated | -29.63% | ||
| ICU - OTLK | 36% Loosely correlated | +1.05% | ||
| GNPX - OTLK | 34% Loosely correlated | +9.57% | ||
| CYTK - OTLK | 33% Loosely correlated | +4.18% | ||
| PDSB - OTLK | 33% Loosely correlated | -0.97% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DLLL | 13.81 | 2.63 | +23.52% |
| GraniteShares 2x Long DELL Daily ETF (DLLL) | |||
| ZHDG | 23.73 | 0.17 | +0.73% |
| Zega Buy & Hedge ETF (ZHDG) | |||
| EPI | 44.30 | 0.06 | +0.14% |
| WisdomTree India Earnings Fund (EPI) | |||
| PCSG | 20.38 | N/A | N/A |
| Polen 5Perspectives Small-Mid Growth ETF (PCSG) | |||
| FTSD | 89.19 | -0.04 | -0.04% |
| Franklin Short Duration U.S. Government ETF (FTSD) | |||